Bispecific antisense olignucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same

A method for making a pharmaceutical composition for treatment of endocrine-regulated cancers, comprising the steps of combining a bispecific antisense oligonucleotide with a pharmaceutically acceptable carrier for intravenous, intraperitoneal, subcutaneous or oral administration, wherein the bispecific antisense oligonucleotide consists essentially of a sequence of bases that is complementary to portions of both the gene encoding IGFBP-2 and the gene encoding IGFBP-5, and which is sufficient length to act as an inhibitor of the effective amount of IGFBP-2 and IGFBP-5.

A method for treating an endocrine-regulated cancer in a subject suffering from the endocrine-regulated cancer, comprising the step of administering to the subject a bispecific antisense oligonucleotide in an amount effective to reduce the effective levels of IGFBP-2 and/or IGFBP-5 in cells of the endocrine-regulated cancer, wherein the bispecific antisense oligonucleotide consists essentially of a sequence of bases that is complementary to portions of both the gene encoding IGFBP-2 and the gene encoding IGFBP-5, and which is sufficient length to act as an inhibitor of the effective amount of IGFBP-2 and IGFBP-5.

A pharmaceutical composition comprising an antisense oligonucleotide and a pharmaceutically acceptable carrier, wherein the bispecific antisense oligonucleotide consists essentially of a sequence of bases that is complementary to portions of both the gene encoding IGFBP-2 and the gene encoding IGFBP-5, and which is sufficient length to act as an inhibitor of the effective amount of IGFBP-2 and IGFBP-5.